Iterum Therapeutics

Melinta Therapeutics

This biopharmaceutical company develops and commercialises antibiotics and antifungals to treat drug-resistant infections in hospital and clinic settings.

Nabriva

This biopharmaceutical company develops and commercialises novel antibiotics for patients with serious infections caused by drug-resistant bacteria.

Paratek Pharmaceuticals

This company develops and commercialises antibiotics and nasal sprays for patients with infectious diseases, pneumonia, skin infections and chronic rhinosinusitis.

TXN Systems

This pharmaceutical company develops a novel class of antibiotics to treat multidrug-resistant urinary tract infections in patients.

Acurx Pharmaceuticals

This biopharmaceutical company develops small molecule antibiotics to treat patients with bacterial infections caused by priority pathogens.

Peninsula Pharmaceuticals

The company develops and commercialises broad-spectrum antibiotics to treat patients with life-threatening infections, including hospital-acquired pneumonia and urinary tract infections.

BioTryp

This company develops oral antibiofilm therapies to treat bacterial infections for patients, primarily focusing on individuals with urinary tract infections.

Durata Therapeutics

The company develops and commercialises intravenous antibiotics to treat patients with acute bacterial skin and skin structure infections.